Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovaza in Mitral Valve Regurgitation
NCT01046604Phase 4Unknown
- Sponsor
- East Carolina University
- Start
- Jan 2010
- Primary completion
- Oct 2013
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid in mitral valve regurgitation (MR), sponsored by East Carolina University. Primary endpoints: Markers of inflammation in atrial myocardium at 15 months and Mitochondrial function in atrial myocardium at 15 months. Status: unknown.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
mitral valve regurgitation (MR)
Beyond the preview
Go deeper on NCT01046604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01046604.